Drug development for the ReproTite product through joint research with the University of Tokyo
First written in FY2018-Q3. 5 of 10 entries say "Restated". Latest entry: FY2021-Q3.
No other company in this theme has enough history to compare yet.
- FY2021-Q3RestatedAnnual report
「Under the Bone Formation Project, the egg-yolk-derived osteogenic peptide ReproTiteⓇ has been selected for the third year of the Practical Research Project for Rare and Intractable Diseases for fiscal 2018 by the Japan Agency for Medical Research and Development (AMED), as a joint research project with the University of Tokyo and Nagasaki University, and research and development are under way. As a drug candidate for osteogenesis imperfecta, the project will continue to pursue partnership discussions with pharmaceutical companies by elucidating ReproTiteⓇ's mechanism of action and evaluating its efficacy and pharmacokinetics in animal models.」
The third year of AMED joint research with the University of Tokyo and Nagasaki University is under way, with continued work on elucidating the mechanism of action, evaluating efficacy and pharmacokinetics, and pursuing partnership discussions with pharmaceutical companies. - FY2021-Q2AdvancedAnnual report
「Under the Bone Formation Project, the egg-yolk-derived osteogenic peptide ReproTiteⓇ has been selected for the third year of the Practical Research Project for Rare and Intractable Diseases for fiscal 2018 by the Japan Agency for Medical Research and Development (AMED), as a joint research project with the University of Tokyo and Nagasaki University, and research and development are under way.」
The AMED joint research on ReproTite has entered its third year, and the project has been selected as a joint research project with Nagasaki University in addition to the University of Tokyo. - FY2021-Q1AdvancedAnnual report
「Under the Bone Formation Project, the egg-yolk-derived osteogenic peptide ReproTiteⓇ has been selected for the third year of the Practical Research Project for Rare and Intractable Diseases for fiscal 2018 by the Japan Agency for Medical Research and Development (AMED), as a joint research project with the University of Tokyo, and research and development are under way. As a drug candidate for osteogenesis imperfecta, the project will continue to pursue partnership discussions with pharmaceutical companies by elucidating ReproTiteⓇ's mechanism of action and evaluating its efficacy and pharmacokinetics in animal models.」
The AMED joint research with the University of Tokyo has entered its third year, moving beyond the previous work on elucidating the mechanism of action and evaluating efficacy to include pharmacokinetic evaluation. - FY2020-Q2RestatedAnnual report
「As a drug candidate for osteogenesis imperfecta, we will investigate the mechanism of action of “ReproTite®” and evaluate its efficacy in animal models while continuing partnership negotiations with pharmaceutical companies.」
Research into ReproTite's mechanism of action, evaluation in animal models and partnership discussions with pharmaceutical companies are continuing. - FY2020-Q1RestatedAnnual report
「As a drug candidate for osteogenesis imperfecta, we will investigate the mechanism of action of “ReproTite®” and evaluate its efficacy in animal models while continuing partnership negotiations with pharmaceutical companies.」
For ReproTite, which is being developed through joint research with the University of Tokyo, research into its mechanism of action, evaluation in animal models and partnership discussions with pharmaceutical companies are continuing. - FY2019AdvancedAnnual report
「Joint research with the University of Tokyo has entered its second year under the Japan Agency for Medical Research and Development (AMED)'s Practical Research Project for Rare and Intractable Diseases, and efficacy against an osteogenesis imperfecta model is being validated.」
Joint research with the University of Tokyo has entered its second year, and ReproTite has progressed to the stage of validating its efficacy against an osteogenesis imperfecta model. - FY2019-Q3RestatedAnnual report
「As a drug candidate for osteogenesis imperfecta, we will investigate the mechanism of action of “ReproTite” and evaluate its efficacy in animal models while pursuing partnership negotiations with pharmaceutical companies.」
Research into ReproTite's mechanism of action, efficacy evaluation in animal models and partnership discussions with pharmaceutical companies are continuing. - FY2019-Q2RestatedAnnual report
「As a drug candidate for osteogenesis imperfecta, we will investigate the mechanism of action of “ReproTite” and evaluate its efficacy in animal models while pursuing partnership negotiations with pharmaceutical companies.」
Research into ReproTite's mechanism of action, efficacy evaluation in animal models and partnership discussions with pharmaceutical companies are continuing. - FY2019-Q1AdvancedAnnual report
「As a drug candidate for osteogenesis imperfecta, we will investigate the mechanism of action of “ReproTite” and evaluate its efficacy in animal models while pursuing partnership negotiations with pharmaceutical companies.」
The project has progressed from the selection stage as a joint research project with the University of Tokyo to the stage of elucidating ReproTite's mechanism of action, evaluating its efficacy in animal models and pursuing partnership discussions with pharmaceutical companies. - FY2018-Q3First statedAnnual report
「ReproTite was selected as a joint research project with the University of Tokyo under the Japan Agency for Medical Research and Development's FY2018 Practical Research Project for Rare and Intractable Diseases. The company will work with the University of Tokyo to assess ReproTite's potential as a drug discovery candidate for a treatment to improve bone fragility in osteogenesis imperfecta, with the aim of developing a pharmaceutical product.」
For ReproTite, the disclosure states for the first time that the project was selected as a joint research project with the University of Tokyo under AMED's fiscal 2018 program, with the aim of validating and developing it as a drug candidate for osteogenesis imperfecta.